• In β -thalassemia major, hepcidin levels are simultaneously associated with erythropoiesis and iron loading pre-and post-transfusion.
Introduction
The mainstay of therapy for β -thalassemia major is lifelong red-cell transfusion to improve anemia and suppress ineffective, expanded erythropoiesis. 1 Ineffective erythropoiesis causes iron overload due to suppression of the liver-derived hormone hepcidin that regulates iron absorption and recycling via its effects on ferroportin, the cellular iron export protein. 2 Low hepcidin preserves ferroportin and permits increased intestinal iron absorption and enhanced macrophage iron release (and hence iron recycling), whereas elevated hepcidin causes degradation of ferroportin, thus decreasing iron absorption and recycling. 3 Hepcidin is suppressed by hypoxia 4 and iron deficiency, 5 and is elevated by iron loading and inflammation. 6 Erythropoiesis is perhaps the most potent suppressor of hepcidin, 7 although the mechanism remains uncertain. The existence of a secreted factor from the erythroid marrow that suppresses hepcidin synthesis has been hypothesized. 7 One candidate, Growth Differentiation Factor-15 (GDF-15), is elevated in ineffective erythropoiesis (especially in thalassemia) and suppresses hepcidin expression in vitro. 8 Ineffective erythropoiesis in thalassemia is suppressed by transfusion. 9 Crosssectional studies suggest that transfused patients with β -thalassemia major have higher hepcidin than non-transfusion dependent patients with β -thalassemia intermedia. 10, 11 Transfusion increases urinary hepcidin in patients with β -thalassemia major. 12 If erythropoiesis measurably fluctuates over the inter-transfusion interval, thalassemia could be a valuable model to study the dynamic regulation of hepcidin in the face of competing influences of coexistent anemia, expanded erythropoiesis and iron loading. Although hemoglobin (Hb) concentrations in non-thalassemic males are
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In a cohort of chronically transfused patients with β -thalassemia major, we hypothesized 1) that pre-and post-transfusion hepcidin concentrations are simultaneously influenced by anemia and erythropoiesis, iron loading and inflammation, 2) that transfusion-mediated increases in Hb suppress erythropoietic drive which, in turn, de-suppresses (raises) hepcidin, and 3) that there are differences in males and females with regard to pre-transfusion erythropoiesis and response to transfusion. We found that hepcidin levels in patients with β -thalassemia major are associated with anemia, erythropoiesis and iron stores; that suppression of erythropoiesis by transfusion is associated with an increase in hepcidin; and that compared with females pre-and post-transfusion, males had increased erythropoiesis and lower hepcidin.
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Methods

Patients
The Southern Health thalassemia service (Melbourne, Australia) is the state center for management of thalassemia. Patients receive red cell transfusions and iron chelators in accordance with international recommendations.
14 Adults with transfusiondependent β -thalassemia were eligible for this study. Blood was collected immediately prior to transfusion, and patients were asked to return five days following transfusion for post-test sampling, when erythroid suppression was expected to correlate with maximal suppression. 15 Data on the transfused units were collected.
Laboratory analysis
Samples were tested for Hb and reticulocyte count (Beckman Coulter LH750), ferritin, soluble transferrin receptor (sTfR) and erythropoietin (EPO) by immunoassay (Beckman Coulter DXi 800), C-reactive protein (CRP) (Beckman Coulter DXc 800), GDF-15 (ELISA, R&D Systems) and hepcidin (EIA, Bachem) .
Normal values and definitions
The reference range for the Beckman Coulter sTfR assay established by the manufacturer in 189 healthy adults is 0.90-2.01 mg/L, mean 1.35mg/L. For EPO, the manufacturer's upper limit of normal is 18.5mIU/mL. Tanno et al suggested GDF-15 levels in normal individuals fall between 200-1150 pg/mL. 16 In a study investigating effects of altitude on erythropoiesis and hepcidin in healthy participants of similar mean age (40 years) to patients in our study, Piperno et al reported baseline mean EPO of 11.5mU/mL and using the same assay, GDF-15 of 338.7 pg/mL. 17 Thus,
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From erythroid activity was evaluated by patient sTfR divided by 1.35 mg/L, 18 patient EPO divided by 11.5 mIU/mL, and patient GDF-15 divided by 338.7 pg/mL. Absolute hepcidin values vary between assays. 19 Using the same assay (Bachem) used in our study, Talbot et al reported mean hepcidin concentrations of 14 ng/mL (standard deviation 11 ng/mL) in healthy adults, 4 and Choi et al identified a range of 3.2-66.9 ng/mL in non-iron deficient Korean children. 20 The hepcidin-ferritin ratio was calculated to normalize hepcidin relative to concomitant iron loading, and should be approximately one in normal controls.
12,21
β -gene mutations were classified as β 0 or β + according to an international database. 22 Blood volume was estimated using Nadler's formula based on sex, weight and height.
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Statistical considerations
Variables with a right-skewed distribution were log-transformed following addition of 1 to approximate a normal distribution, a standard procedure to enable parametric analysis of skewed data. 17 Geometric means were calculated by exponentiation of the arithmetic mean of the log-variable, followed by subtraction of 1. Student's t-test was used to compare means between groups or pre-and post-transfusion. Pearson's correlation was used to assess associations between indices. Change from pre to posttransfusion was evaluated by calculation of difference (post-transfusion minus pretransfusion) where variables were normally distributed, and percentage change where variables were skewed. Univariate and then multiple linear regression was used to evaluate the independent relationship between included variables and hepcidin preand post-transfusion. Standardized (beta) coefficients were calculated (where variables are standardized to have a variance of 1) to enable comparison between variables. The study had a power of 0.80 to detect a difference of 25% in normally
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Ethics approval
The Southern Health Human Research Ethics Committee approved the study. All patients provided written consent in accordance with the Declaration of Helsinki.
Results
Pre-transfusion
Thirty-one (male n=16; female n=15) patients with β -thalassemia major (β 0 /β 0 =3,
, Eβ-thalassemia=1, unknown=2) provided pre-transfusion samples (Table 1) . The mean duration since previous transfusion was 22 days [range 13-36].
Twenty-seven patients were receiving chelation with deferasirox (daily or twicedaily) and four with desferrioxamine (four to six nights per week). /L (within the normal range). Based on the sTfR, mean relative erythroid activity was 2.1. EPO (4.8×mean) and GDF-15 (22.3×mean) levels were also increased. Pre-transfusion hepcidin concentrations were within the range reported in normal adults and children, however, the hepcidin-ferritin ratio was markedly below 1 in all patients (mean 0.018), indicating suppression of hepcidin out of proportion with the degree of iron loading.
12,24
There were no associations between duration since previous transfusion and any pretransfusion index. 
Associations between pre-transfusion indices and hepcidin
Figure 2 presents associations between pre-transfusion Hb, indices of erythropoiesis and hepcidin. Pre-transfusion Hb was inversely associated with indices of erythropoiesis (EPO and GDF-15 but not sTfR). Table 2 presents results of univariate and multiple linear regression for associations with pre-transfusion hepcidin.
Hepcidin was positively associated with Hb and ferritin, and inversely with EPO, sTfR and GDF-15. Women had higher hepcidin levels.
Four multiple linear regression models adjusted for sex were developed to evaluate simultaneous co-regulation of hepcidin by iron loading (ferritin) and anemia/erythropoiesis (measured by Hb, EPO, GDF-15 and sTfR respectively) ( Table   2 ). One index of erythropoiesis or anemia was included per model. As CRP was not associated with hepcidin, it was not considered further. The models show that controlling for sex, iron stores and erythropoiesis simultaneously influence hepcidin, with these factors explaining about half the variance in hepcidin (as indicated by the R 2 ).
Post-transfusion
Twenty-six patients returned after a mean of six days for post-transfusion sampling.
There were no differences in age, sex, or pre-transfusion iron loading, Hb, indices of erythropoiesis and hepcidin between patients who did and did not return. Change in Hb and indices of erythropoiesis, ferritin, CRP and hepcidin are presented in Figure 1 .
In every patient, Hb and hepcidin increased (other than one in whom hepcidin remained undetectable) and EPO and GDF-15 fell. Change in sTfR was Associations between changes in GDF-15 and hepcidin were not evident, nor was change in ferritin and hepcidin associated.
Comparisons between males and females
Male and female patients were of similar age, duration since previous transfusion, time to return post-transfusion, and pre-transfusion Hb and reticulocyte count. Male patients were heavier, taller and had higher blood volumes than females (Table 1) .
Although male patients were transfused a similar number of units (absolute and mL/kg) compared with females, male patients received a lower transfusion volume per liter blood volume compared with their female counterparts.
Comparisons of Hb, indices of erythropoiesis, ferritin and hepcidin between the sexes are presented in Table 3 . Pre-transfusion, male patients had higher sTfR and GDF-15
(indicating higher relative erythropoiesis), lower ferritin and lower hepcidin compared with females. Post-transfusion, males had significantly lower Hb, higher reticulocyte count, lower ferritin, higher sTfR and GDF-15 (with EPO approaching significance, p=0.053), and lower hepcidin compared with females.
Age of blood
Finally, post-hoc analysis was performed to study associations between age of the red cell units (defined as duration between collection date and transfusion date) and changes in Hb, erythropoiesis and ferritin. The mean age of units transfused was 16.1 days. In one patient, all transfused units were 7 days or younger; in a further 6 In all patients, the hepcidin-ferritin ratio was markedly below one both pre-and post transfusion, indicating suppression of hepcidin out of proportion to the degree of iron loading, and implying a suppressive effect from erythropoiesis. 12 Although ferritin rose post-transfusion, it is unlikely that increasing iron stores caused the rise in hepcidin as percentage changes in hepcidin and ferritin were not correlated.
Furthermore, the rise in the hepcidin-ferritin ratio following transfusion despite the increase in ferritin indicates that hepcidin increased out of proportion to the increase in ferritin.
The mechanism for suppression of hepcidin in patients with thalassemia and other conditions with increased erythropoiesis remains uncertain but several lines of evidence suggest an erythropoiesis-derived signal that inhibits hepcidin production.
Sera from thalassemic patients suppresses Hamp expression in hepatoma cell lines, 8, 36 indicating the presence of the signal in serum and activity in vitro. The suppressive signal appears to override iron loading induced-BMP6 mediated signaling. factor that suppresses hepcidin.
Guidelines for the management of β -thalassemia major advise transfusion to maintain 
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Adoption of these pre-transfusion Hb targets reduced transfusion requirements and eased iron loading. 44 In our study, patients were receiving an individualized, stable, regular transfusion regimen based on their tolerable transfusion volume and a clinically and logistically acceptable inter-transfusion interval. Pre-transfusion erythroid activity (defined by sTfR) was 1-4 times normal in 24 of 28 patients with Hb>90g/L, thus our data support current recommendations.
Previous studies reporting erythropoiesis and hepcidin in thalassemia did not present comparisons between males and females. Multiple regression indicated that pre-and post-transfusion sex differences in hepcidin levels are partially mediated by sex-wise differences in blood volume, which may result in males receiving a relatively smaller transfusion volume. We also noted that male patients had lower ferritin concentrations compared with females. Although relatively lower transfusion volumes could be one explanation, differences in dosing and adherence to iron chelators also need to be considered. Although weight and height were inversely associated with hepcidin and positively with sTfR and GDF-15 (data not shown), these associations were no longer seen when controlling for sex. As the number of subjects in our study was relatively small, studies in other thalassemia patient groups are needed to establish whether sex-wise differences observed here are present more generally.
Earlier studies in transfused children with β -thalassemia major showed that when children were anemic and transfusions delayed, iron absorption from ferrous sulfate and food is increased, whereas absorption is normal when measured shortly following transfusion when Hb is raised, predicting an interaction between erythropoiesis and hepcidin many years before hepcidin was discovered. Compared with transfusion of fresh blood, aged (40-42 day old) blood has been found to produce greater increases in serum ferritin, transferrin saturation and nontransferrin bound iron in healthy volunteers. 49 We did not find evidence of an effect of blood storage age on changes in ferritin. However, only few patients received exclusively fresh units and further studies are needed to evaluate the effects of blood storage in β -thalassemia.
Unlike mouse models of thalassemia, 2 age was not associated with hepcidin levels.
This association may be mediated by iron loading and may be modified by chelator adherence. One patient appeared an outlier in our dataset: a 40-year-old male with pre-transfusion Hb=66g/L; EPO=244.7IU/mL, sTfR=4.1mg/mL, GDF-15=33,464pg/mL, hepcidin undetectable; post-transfusion Hb=84g/L, EPO=160.5IU/mL, GDF-15=21,931pg/mL, hepcidin remained undetectable. The patient was retained in the analysis as he fulfilled inclusion criteria and recorded data were accurate. If this patient was excluded from the analysis, pre-transfusion multiple (together with the hepcidin-ferritin ratio) may become a useful indicator of erythropoiesis and iron kinetics in complex patients. Our data also suggest that, reflecting the situation in non-thalassemic individuals, optimal pre-transfusion hemoglobin levels in males with β -thalassemia may be higher than for female patients, although corroboration in other cohorts is necessary. In all patients, the hemoglobin increment is related to the transfusion volume relative to patient blood volume, and thus incorporation of the recipient blood volume into transfusion dosage calculations may be useful. 
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